Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed 31/08/2022) TEPADINA thiotepa 100mg powder for concentrate for solution for infusion injection (UK)
Section 19A approved medicine
(Approval lapsed 31/08/2022) TEPADINA thiotepa 100mg powder for concentrate for solution for infusion injection (UK)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 517
Phone
1800 181 060
Approved until
Status
Lapsed
Indication(s)
TEPADINA is indicated, in combination with other chemotherapy medicinal products:
- with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;
- when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.